The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. The half the patients will receive metformin in combination with androgen deprivation therapy (ADT) and abiraterone, and the other half will receive ADT and abiraterone only.

Clinical Trial Description

Metastatic hormone-sensitive prostate cancer (mHSPC) can be treated with androgen-deprivation therapy (ADT) alone, ADT plus abiraterone, ADT plus enzalutamide, ADT plus apalutamide, ADT plus docetaxel. However, most patients eventually progress to castration-resistant prostate cancer (CRPC) and die of the disease. Therefore, there is still a need to improve the therapeutic effect for mHSPC. Many studies have shown that metabolic syndrome and its components are associated with increased development and progression of aggressive prostate cancer. Metformin, a common well-tolerated oral biguanide prescribed for type II diabetes, could be used to decrease the risk of prostate cancer development and improve the efficacy of treatment. Some studies reported that metformin could enhance the effectiveness of ADT, and improve recurrence-free survival, overall survival and cancer-specific survival. A prospective randomized study reported that metformin potentially lengthen time to CRPC in advanced prostate cancer patients when combined with ADT especially in those with high risk localized prostate cancer, clinically node positive and in those with low tumor volume metastatic hormone-sensitive patients. After extensive research, there is no published results from prospective randomized trials evaluating the effect of metformin in combination with ADT and abiraterone among patients with newly diagnosed mHSPC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04925063
Study type	Interventional
Source	Sun Yat-sen University
Contact	Yonghong Li, M.D.
Phone	86-13711376697
Email	liyongh@sysucc.org.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	June 16, 2021
Completion date	August 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT03554317` - COMbination of Bipolar Androgen Therapy and Nivolumab	Phase 2
Recruiting	`NCT04533958` - Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy	N/A
Not yet recruiting	`NCT06009549` - A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
Withdrawn	`NCT05771896` - Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC	Phase 3
Completed	`NCT01981122` - A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer	Phase 2
Completed	`NCT01233557` - Biomarkers of Bone Resorption in Metastatic Prostate Cancer	N/A
Completed	`NCT01012141` - Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT04067713` - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
Active, not recruiting	`NCT04332744` - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)	Phase 2
Completed	`NCT04545697` - mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer	N/A
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Not yet recruiting	`NCT04031378` - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer	Phase 2
Completed	`NCT02278055` - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer	Phase 2
Completed	`NCT04193657` - Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Completed	`NCT02260817` - Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer	Phase 3
Terminated	`NCT00216060` - Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy	Phase 3
Recruiting	`NCT04070209` - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)	Phase 2
Recruiting	`NCT04925648` - Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Phase 2
Completed	`NCT01303705` - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.